secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001213900-23-037951
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics Q1 net loss $2.5M, cash $6.8M; focuses on FDA pathway
-------------------------------------------------------------------------

- Net loss of $2.5M ($0.12/shr) vs $2.0M ($0.10/shr) in Q1 2022.
- Cash and equivalents fell to $6.8M at March 31, 2023 from $10.1M at Dec 31, 2022.
- R&D expense rose to $1.4M from $695k, driven by clinical trial and personnel costs.
- CEO notes resources aligned with FDA feedback to optimize Symphony IL-6 approval pathway.
- No revenue reported; pre-commercial stage diagnostics company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/0001213900-23-037951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/ea178223-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-037951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer